Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Mega Lifesciences Yönetim

Yönetim kriter kontrolleri 2/4

Mega Lifesciences' CEO'su Vivek Dhawan, Jan1988 tarihinde atandı, in görev süresi 36.75 yıldır. şirketin hisselerinin 6.59% doğrudan sahiptir ve bu hisselerin değeri THB 2.29B dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 26.8 yıl ve 11.7 yıldır.

Anahtar bilgiler

Vivek Dhawan

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	36.8yrs
CEO sahipliği	6.6%
Yönetim ortalama görev süresi	26.8yrs
Yönetim Kurulu ortalama görev süresi	11.7yrs

Son yönetim güncellemeleri

Recent updates

CEO

Vivek Dhawan (63 yo)

36.8yrs

Görev süresi

Mr. Vivek Dhawan has been the Chief Executive Officer of Mega Lifesciences Public Company Limited since 1988 and has been its Chief Coach since 2013. Mr. Dhawan started with Medicap and built Lupin Laborat...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Vivek Dhawan	CEO, Chief Coach & Executive Director	36.8yrs	Veri yok	6.59% THB 2.2b
Thomas Abraham	CFO & Executive Director	26.8yrs	Veri yok	0.76% THB 256.7m
Deepak Panjwani	Chief Risk & Compliance Officer	no data	Veri yok	Veri yok
Paramjit Sawhney	President of International	no data	Veri yok	1.5% THB 503.8m
Girish Wadhwa	President of Myanmar	no data	Veri yok	Veri yok
Manoj Gurbuxani	Deputy Chief Financial Officer	4.8yrs	Veri yok	Veri yok
Duangnapa Tongsiri	President of Mega We Care Thailand	no data	Veri yok	1.48% THB 496.0m
Sujintana Boonworapat	Corporate Secretary	no data	Veri yok	Veri yok

26.8yrs

Ortalama Görev Süresi

57.5yo

Ortalama Yaş

Deneyimli Yönetim: MEGA 'un yönetim ekibi deneyimli ve deneyimlidir ( 26.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Vivek Dhawan	CEO, Chief Coach & Executive Director	11.8yrs	Veri yok	6.59% THB 2.2b
Thomas Abraham	CFO & Executive Director	26.8yrs	Veri yok	0.76% THB 256.7m
Yim Chi	Independent Vice Chairma	11.7yrs	฿1.58m	Veri yok
Kirit Chimanlal Shah	Non-Executive Director	11.7yrs	฿661.50k	49.81% THB 16.7b
Shiraz Poonevala	Non-Executive Director	11.7yrs	฿661.50k	Veri yok
Ishaan Shah	Non-Executive Director	11.7yrs	฿661.50k	Veri yok
Mechai Viravaidya	Independent Chairman	11.7yrs	฿2.21m	Veri yok
Sameera Shah	Non-Executive Director	11.7yrs	฿661.50k	Veri yok
Thor Santhisiri	Independent Director	11.7yrs	฿1.15m	Veri yok
Vijay Karwal	Independent Director	3.4yrs	฿1.15m	Veri yok
Nithinart Sinthudeacha	Independent Director	1.8yrs	฿1.15m	Veri yok

11.7yrs

Ortalama Görev Süresi

62yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: MEGA 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 11.7 yıldır).

Mega Lifesciences Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Less than half of directors are independent

Less than half of directors are independent

Mega Lifesciences Public Company Limited Appoints Alan Kam to Be the Vice Chairman of the Board of Directors

Mega Lifesciences Public Company Limited, Annual General Meeting, Apr 05, 2022

Mega Lifesciences Public Company Limited, Annual General Meeting, Apr 05, 2021

Recent updates

First half dividend of ฿0.80 announced

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

First quarter 2024 earnings released: EPS: ฿0.55 (vs ฿0.52 in 1Q 2023)

Upcoming dividend of ฿0.80 per share

Final dividend reduced to ฿0.80

Mega Lifesciences Public Company Limited Proposes Dividend for the Year Ended December 31, 2023, Payable on April 22, 2024

Full year 2023 earnings released: EPS: ฿2.29 (vs ฿2.57 in FY 2022)

Now 20% undervalued

Mega Lifesciences Public Company Limited to Report Q3, 2024 Results on Nov 12, 2024

Third quarter 2023 earnings: EPS misses analyst expectations

Now 21% undervalued

Now 21% undervalued

Upcoming dividend of ฿0.80 per share at 3.8% yield

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Mega Lifesciences Public Company Limited Announces Cash Dividend for the Period from January 1, 2023to June 30, 2023, Payable on September 8, 2023

Now 20% undervalued after recent price drop

Mega Lifesciences Public Company Limited to Report Q2, 2023 Results on Aug 11, 2023

Now 25% undervalued after recent price drop

First quarter 2023 earnings: EPS misses analyst expectations

Now 22% undervalued after recent price drop

Upcoming dividend of ฿0.85 per share at 3.5% yield

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Now 21% undervalued after recent price drop

Upcoming dividend of ฿0.75 per share

Second quarter 2022 earnings: Revenues exceed analyst expectations

Mega Lifesciences Public Company Limited Announces Cash Dividend for the Period from January 1, 2022 to June 30, 2022, Payable on September 9, 2022

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Mega Lifesciences Public Company Limited Appoints Alan Kam to Be the Vice Chairman of the Board of Directors

Upcoming dividend of ฿0.86 per share

Mega Lifesciences Public Company Limited, Annual General Meeting, Apr 05, 2022

Mega Lifesciences Public Company Limited Proposes Dividend for Year Ended December 31, 2021, Payable on April 22, 2022

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Now 21% undervalued

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS ฿0.70 (vs ฿0.39 in 3Q 2020)

Investor sentiment improved over the past week

Upcoming dividend of ฿0.52 per share

Second quarter 2021 earnings released: EPS ฿0.58 (vs ฿0.35 in 2Q 2020)

First quarter 2021 earnings released: EPS ฿0.38 (vs ฿0.37 in 1Q 2020)

New 90-day low: ฿35.50

Mega Lifesciences Public Company Limited, Annual General Meeting, Apr 05, 2021

Revenue and earnings beat expectations

Full year 2020 earnings released: EPS ฿1.60 (vs ฿1.31 in FY 2019)

New 90-day high: ฿40.50

New 90-day high: ฿39.00

Third quarter 2020 earnings released: EPS ฿0.39

Revenue and earnings beat expectations

New 90-day low: ฿32.00

New 90-day low: ฿33.00

Mega Lifesciences Public Company Limited (SET:MEGA) completed the acquisition of 83.33% stake in PT Futamed Pharmaceuticals from PT Ersons and others for approximately IDR 180 billion.

CEO

Görev süresi

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş